These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27299299)

  • 41. Gene Therapy Approaches to Hemoglobinopathies.
    Ferrari G; Cavazzana M; Mavilio F
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
    Sadelain M
    Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic therapies for the first molecular disease.
    Doerfler PA; Sharma A; Porter JS; Zheng Y; Tisdale JF; Weiss MJ
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33855970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in sickle cell therapies in the hydroxyurea era.
    Field JJ; Nathan DG
    Mol Med; 2014 Dec; 20 Suppl 1(Suppl 1):S37-42. PubMed ID: 25549232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sickle Cell Disease: From Genetics to Curative Approaches.
    Hardouin G; Magrin E; Corsia A; Cavazzana M; Miccio A; Semeraro M
    Annu Rev Genomics Hum Genet; 2023 Aug; 24():255-275. PubMed ID: 37624668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Definitive Erythropoiesis from Pluripotent Stem Cells: Recent Advances and Perspectives.
    Demirci S; Tisdale JF
    Adv Exp Med Biol; 2018; 1107():1-13. PubMed ID: 29876866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
    Payen E; Leboulch P
    Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delta-globin gene expression improves sickle cell disease in a humanised mouse model.
    Porcu S; Simbula M; Marongiu MF; Perra A; Poddie D; Perseu L; Kowalik MA; Littera R; Barella S; Caria CA; Demartis FR; Ristaldi MS
    Br J Haematol; 2021 Jun; 193(6):1228-1237. PubMed ID: 34046885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease.
    He Z; Russell JE
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10635-40. PubMed ID: 12124399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical genome editing to treat sickle cell disease-A brief update.
    Zarghamian P; Klermund J; Cathomen T
    Front Med (Lausanne); 2022; 9():1065377. PubMed ID: 36698803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease.
    Hart KL; Liu B; Brown D; Campo-Fernandez B; Tam K; Orr K; Hollis RP; Brendel C; Williams DA; Kohn DB
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101254. PubMed ID: 38745893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy.
    Bernardo ME; Aiuti A
    Hum Gene Ther; 2016 Oct; 27(10):741-748. PubMed ID: 27530055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic therapy for beta-thalassemia: from the bench to the bedside.
    Arumugam P; Malik P
    Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Smoothing the crescent curve: sickle cell disease.
    Talano JA; Cairo MS
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):468-74. PubMed ID: 25696896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inositol hexaphosphate-loaded red blood cells prevent in vitro sickling.
    Bourgeaux V; Hequet O; Campion Y; Delcambre G; Chevrier AM; Rigal D; Godfrin Y
    Transfusion; 2010 Oct; 50(10):2176-84. PubMed ID: 20456710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease.
    Justus DG; Manis JP
    Transfus Apher Sci; 2021 Feb; 60(1):103059. PubMed ID: 33541761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
    Locatelli F; Pagliara D
    Pediatr Blood Cancer; 2012 Aug; 59(2):372-6. PubMed ID: 22544533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient-specific modeling of individual sickle cell behavior under transient hypoxia.
    Li X; Du E; Dao M; Suresh S; Karniadakis GE
    PLoS Comput Biol; 2017 Mar; 13(3):e1005426. PubMed ID: 28288152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular therapy for sickle cell disease.
    Abraham A; Jacobsohn DA; Bollard CM
    Cytotherapy; 2016 Nov; 18(11):1360-1369. PubMed ID: 27421743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.